Tango Therapeutics is a clinical-stage precision oncology biotechnology company headquartered in Boston, Massachusetts, focused on synthetic lethality to target tumor suppressor gene loss, including MTAP deletions. In October 2026, following encouraging ESMO Phase 1/2 clinical combination data for its MTA-cooperative PRMT5 inhibitor vopimetostat paired with Revolution Medicines' RAS(ON) inhibitors in metastatic pancreatic ductal adenocarcinoma (PDAC), Tango cut 14% of its workforce (~19 discovery roles) to halt novel target discovery and concentrate resources on advancing vopimetostat into registrational Phase 3 trials alongside CNS-penetrant PRMT5 inhibitor TNG456.
Planned initiation of registrational Phase 3 trial for vopimetostat in MTAP-deleted pancreatic cancer
Tango Therapeutics cut 14% of its workforce (~19 discovery roles) and halted novel preclinical target discovery to focus capital on advancing its clinical MTA-cooperative PRMT5 inhibitors—vopimetostat (TNG462) and brain-penetrant TNG456—following ESMO Phase 1/2 pancreatic cancer combination data with Revolution Medicines' RAS(ON) inhibitors.
Boston-based Tango Therapeutics laid off 14% of its staff (~19 discovery roles) to halt novel target discovery and concentrate capital on its clinical PRMT5 inhibitors vopimetostat and TNG456 after reporting strong Phase 1/2 pancreatic cancer combination data with Revolution Medicines.
President and Chief Executive Officer
President, Research and Development
Chief Financial Officer
No active job listings. Check back later.